Presentations

Recent Presentations

Etzioni R. “Hoping to Be Useful in a Pandemic: Collaborating with the Washington State Department of Health on Statewide COVID-19 Control”   JSM 2021 Online August 2021.

Etzioni R. “From Data to Evidence: Using Modelling to Make the Most out of Early Detection Research Studies” Keynote Address, Cambridge Early Detection Annual Symposium, Cancer Research UK, January 2020

Etzioni R. “Statistical Methods to Support the Estimation of Overdiagnosis in Screening-detectable Cancers” UCL International Alliance for Cancer Early Detection Lecture Series, University College, London, January 2020

ETzioni R. “Recurrence using Claims and PROs for SEER Enhancement: The ReCAPSE Project,” NCI-CRUK symposium on Cancer Recurrence and Cancer Registries, London, March 2019

Etzioni R. “Estimating overdiagnosis in cancer screening: Overcoming Challenges, Avoiding Mistakes,” Keynote Speaker at the UniSante symposium on Overdiagnosis, Lausanne, Switzerland, March 2019

Etzioni R. “Cancer risk prediction: sidekick or critical partner in cancer early detection.” Harvard School of Public Health, Symposium in Honor of the Opening of the Xu Family Center for Global Cancer Prevention, February 2019

Nyame YA, Gulati R, Gore JL, Etzioni R. “Does comorbidity influence primary treatment and prostate cancer specific mortality? Evidence from men with localized disease in SEER-Medicare.” Annual Prostate Cancer Program Retreat, Fort Lauderdale FL, March 2019.Gulati R, Etzioni R. “Conditions for valid estimation of cancer overdiagnosis using excess incidence from screening trials.” International Conference on Econometrics and Statistics, Taichung, Taiwan, June 2019.

Etzioni R. “What does it mean to work in health policy statistics?” Invited discussant, Joint Statistical Meetings, Vancouver, Canada, August 2018.

Etzioni R. “Reconciling disease progression risks across multiple clinical cohorts.” Joint Statistical Meetings, Vancouver, Canada, August 2018.

Gulati R, Lange JM, Etzioni R. “Implications of novel biomarker-based tests for early detection: The case of prostate cancer screening.” AcademyHealth Annual Research Meeting, Seattle WA, June 2018.

Gulati R, A’mar T, Morgan TM, Etzioni R. “Prostate cancer screening using personalized testing intervals and cessation age.” AcademyHealth Annual Research Meeting, Seattle WA, June 2018.

Etzioni R, Lange JM, Gulati R. “Should black men be screened for prostate cancer more intensively?” AcademyHealth Annual Research Meeting, Seattle WA, June 2018.

Etzioni R. “Evidence-based cancer policy: Taking statistical aim at a perpetually moving target.” Prentice Lecture, Seattle WA, May 2018.

Etzioni R. “Narrowing the racial divide in prostate cancer: Disparity in effort for parity in outcomes?” AACR Annual Meeting, Chicago IL, April 2018.

Etzioni R. “Prostate cancer isn’t colorblind.” Fred Hutchinson Cancer Research Center prostate program seminar, Seattle WA, January 2018.

Etzioni R. “Simulation modeling of prostate cancer screening:  A powerful tool for policy development and medical decision making.” International Conference on Health Policy Statistics, Charleston, SC, January 2018.

Etzioni R. “Overdiagnosis in cancer screening: A clinical problem in search of a statistical solution.” Vanderbilt Center for Quantitative Sciences, November 2017.

Etzioni R.  “Bridging the gaps in the evidence base for prostate cancer screening.” Grand Rounds, Department of Urology, Vanderbilt University, November 2017.

Etzioni R. “Cancer recurrence modeling: Is the whole equal to the sum of its parts?” CISNET Annual Meeting Plenary Session, Washington DC, November 2017.

Etzioni R. “Prostate cancer screening: a review of the evidence.” American Cancer Society Early Detection Panel Annual Meeting, Atlanta GA, October 2017.

Etzioni R. “Bridging the gaps in evidence-based oncology.” Oregon Health Science University and Knight Cancer Center Weekly seminar, Portland OR, September 2017.

Etzioni R. “Using modeling to learn about racial differences in prostate cancer.” Biometrics Society WNAR Meeting, Santa Fe NM, June 2017.

Etzioni R. “Risk-stratified screening: From principle to practice.” Canary Foundation Early Detection Symposium, Palo Alto CA, May 2017.

Etzioni R. “Cancer screening: Evidence, opinion and fact.” Dialogue on Cancer, Prevent Cancer Foundation, Washington DC, April 2017.

Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. “Targeted screening for cancer: Tailoring policy to biological mechanism.” Annual Prostate Cancer Program Retreat, Fort Lauderdale FL, March 2017.

Etzioni R. “EHR data and Bayesian analysis: The tail wagging the dog?” Biometrics Society ENAR Meeting, Washington DC, March 2017.

Etzioni R. “A modeling framework to prioritize interventions for breast cancer control.” World Cancer Congress, Paris, France, October 2016.

Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. “Targeted screening for cancer: Tailoring policy to biological mechanism.” Society for Medical Decision Making, Vancouver, Canada, October 2016.

Etzioni R. “Quantifying overdiagnosis in breast cancer: How many DCIS cases are overdiagnosed?” COMET trial stakeholder advisory board meeting, Baltimore MD, February 2017.

Etzioni R. “Overdiagnosis in cancer screenings: overcoming challenges, avoiding mistakes.” NIH web series, "Medicine: Mind the Gap," November 2016.

Etzioni R. “Estimating overdiagnosis from trials and populations: Overcoming challenges, avoiding mistakes.” Preventing Overdiagnosis 2015, Barcelona, Spain, September 2016.

Etzioni R. “The good, the bad and the messy: Statistical inference from electronic medical records.” Invited discussant, Joint Statistical Meetings, Chicago IL, August 2015.

Etzioni R. “Comparing comparative effectiveness studies using EHR data: Application to active surveillance in prostate cancer.” ENAR Spring Meeting, Austin TX, March 2016.

Etzioni R. “A framework for salvage treatment decision making at prostate cancer recurrence.” Dana Farber Cancer Institute, Boston MA, March 2016.

Etzioni R. “Are results from historical mammography trials still relevant today? A model-based analysis for informing policy decisions.” University of Massachusetts, Worcester MA, March 2016.

Etzioni R. “Workshop in getting the numbers right in cancer screening.” Prevent Cancer Foundation’s Annual Dialogue on Cancer, Baltimore MD, February 2016.

Etzioni R. “Opportunities in Early Detection Research and Screening Policy Development.” AACR Cancer Prevention Summit, Leesburg, VA, February 2016.

Etzioni R. “Projecting the clinical harms and benefits of novel biomarker-based tests for cancer screening and biopsy targeting.” iBRIGHT: Integrative Biostatistics Research for Imaging, Genomics & High-throughput Technologies in Precision Medicine, MD Anderson Cancer Center, Houston TX, October 2015.

Etzioni R. “Limitations of screening trials in developing screening policies.” Joint Statistical Meetings, Seattle WA, August 2015.

Etzioni R. “PSA screening for prostate cancer: Evidence versus efficacy.” Symposium on Applying Epidemiologic Discoveries to Reduce Cancer Burden, National Cancer Institute, June 2015.

Etzioni R. “Estimating overdiagnosis in breast and prostate cancer screening: Methods and Challenges.” International Cancer Screening Network Meeting, Rotterdam, Netherlands, July 2015. 

Etzioni R. “Estimating overdiagnosis in breast (and prostate) cancer screening: A problem of excess proportions.” UCLA Biostatistics Department Seminar, Los Angeles CA, April 2015.

Etzioni R. “Applying epidemiologic discoveries to reduce cancer burden.” Biometrics Society ENAR Meeting, Miami FL, March 2015.

Etzioni R. “Interpreting cancer screening studies.” Dialogue for Action Conference of the Prevent Cancer Foundation, Baltimore MD, March 2015.

Etzioni R. “Overdiagnosis in prostate cancer screening.” North American Association of Central Cancer Registries Meeting, Ottawa, Canada, 2014.

Etzioni R. “PSA screening: Many questions, some answers?” University of California, San Francisco, Department of Urology Grand Rounds, San Francisco CA, February 2014.

Etzioni R. “Overdiagnosis in breast and prostate cancer screening: Methods, concepts and mistakes.” Invited Speaker, Joint Statistical Meetings, Montreal, Canada, August 2013.

Etzioni R. “Translating evidence into policy: The case of prostate cancer screening.” Canadian Center for Applied Research in Cancer Control, Annual Conference, Vancouver, Canada, May 2013.

Etzioni R. “What we can (and cannot) learn from ERSPC and PLCO.” PSA Screening Short Course, American Urology Association Annual Meeting, May 2013.

Etzioni R. “An overview of CISNET and CISNET prostate modeling projects.” European Randomized Study of Prostate Cancer Screening Semi-Annual Meeting, Goteborg, Sweden, May 2013.

Etzioni R. “Navigating the maze of data on prostate cancer screening and treatment.” Mayo School of Continuous Professional Development, Phoenix AZ, January 2013.

Etzioni R. “The 'D' recommendation for prostate cancer screening: Difficult data deserve due diligence.” Northwest Urologic Society Annual Meeting, Bellevue WA, December 2012.

Etzioni R. “The 'D' recommendation for prostate cancer screening: Difficult data deserve due diligence.” Society of Urologic Oncology Annual Meeting, Rockville MD, November 2012.

Etzioni R. “Projecting the absolute risk of latent prostate cancer: A path to quantifying overdiagnosis.” NIH Biostatistics Symposium, Bethesda MD, November 2012.

Etzioni R. “How many prostate cancers are overdiagnosed? Overcoming challenges and avoiding mistakes.” Forum on Overscreening, Overdiagnosis, and Overtreatment in Cancer: The Prostate Example, Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research, Anaheim CA, October 2012.

Gulati R, Etzioni R. “Modeling prostate cancer: Innovations and insights.” Economics, Modeling, and Diabetes: The Mt Hood 2012 Challenge, Baltimore MD, June 2012.

Etzioni R. “Avoiding overdiagnosis and overtreatment of common cancers.” ASCO Annual Meeting, Chicago IL, June 2012.

Etzioni R. “Statistical perspectives on PSA testing.” PSA: A Town Hall Debate, American Urology Association Annual Meeting, Atlanta GA, May 2012.

Etzioni R. “Can prostate screening be saved?” 8th Annual Canary Symposium, Stanford CA, May 2012.

Etzioni R. Invited speaker at Workshop on Methodology and Applications in Evaluation of Service Screening for Cancer, London, UK, January 2012.

Etzioni R. “Understanding – and responding to – the new 'D' recommendation for PSA screening from the USPSTF.” McGill University, Montreal, Canada, October 2011.

Etzioni R. “A statistician at the policy table: Integrating modeling into the development of public health guidelines.” Speaker with Lunch, Health Policy Statistics Section, Joint Statistical Meetings, Vancouver, Canada, August 2010.

Gulati R, Inoue LY, Etzioni R. “A quadratic regression approach to maximize the mean simulated likelihood in microsimulation models with few parameters.” Joint Statistical Meeting, Vancouver, Canada, August 2010.

Etzioni R. “Modeling and cancer screening.” Division of Cancer Control and Population Sciences Cancer Screening Think Tank, National Cancer Institute, Bethesda MD, July 2010.

Etzioni R. “Prostate cancer screening: What do we know and what can we recommend?” Epidemiology Meets Heath Policy, Symposium for the North American Congress of Epidemiology, Montreal, Canada, June 2011.

Etzioni R. “PSA screening: Benefit at what cost?” Frontiers in Cancer Prevention Research Conference sponsored by the American Association for Cancer Research, Houston TX, December 2009.

Etzioni R. Invited participant, Cancer Surveillance Planning Workshop, National Cancer Institute, Bethesda MD, November 2009.

Etzioni R. “Simulation modeling to interpret trends in cancer mortality: The case of prostate cancer.” Workshop on Methods and Applications for  Population-Based Survival, Villa Mondragone, Italy, September 2009.

Etzioni R. “Modeling drivers of cost and benefit for policy development in cancer,” Workshop on Combining Epidemiology and Economics for Measurement of Cancer Costs, Villa Mondragone, Italy, September 2009.

Etzioni R, Gulati R, Katcher J, Inoue L. “A surveillance model of prostate cancer trends can inform screening policies.” International Microsimulation Association General Meeting, Ottawa, Canada, July 2009.

Gulati R, Katcher J, Inoue L, Etzioni R. “Joint modeling of biomarker growth and disease progression: An approach for interpreting prostate cancer mortality trends in the population.” CISNET-ICBP Joint Workshop, Washington DC, March 2009.

Etzioni R. “CISNET Prostate: Macro-level models of disease mortality seeking micro-level assistance.” CISNET-ICBP Joint Workshop, Washington DC, March 2009.

Gulati R, Katcher J, Hazelton W, Etzioni R. “A linked biomarker-disease progression model calibrated to US population to inform prostate cancer policy development.” Society for Medical Decision Making, Pittsburgh PA, October 2008.